Eisai Obtains Rights To Overactive Bladder Agent Uritos In 13 Asian Countries
This article was originally published in PharmAsia News
Japanese drug maker Kyorin Pharmaceutical signed a licensing agreement with Eisai Sept. 29 giving Eisai exclusive rights to develop and market overactive bladder agent Uritos (imidafenacin) in China, India, Sri Lanka and 10 ASEAN countries
You may also be interested in...
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Digital Health Roundup, March 2021: Record-Breaking Funding; Exec Chats With Medtronic, Edwards LifeSciences
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news to date.
Natural hair-care, clean skin-care and sustainable soap brands announce new funding to support their growth objectives, citing their positive impacts on people and the environment as key draws.